idhifa® (enasidenib) for relapsed/refractory aml | for hcps
discover idhifa® (enasidenib), an idh2 inhibitor for relapsed/refractory acute myeloid leukemia (aml) with an idh2 mutation. see safety information and boxed warning on differentiation syndrome.
Address
Tel
Website
Date
|
Product Description
|
Supplier
|
Money
|
Quantity
|
Weight
|
---|
idhifapro's website is idhifapro.com